Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas?
A large body of evidence suggests that the abnormal phenotype of neoplastic astrocytes, including their excessive proliferation rate and high propensity to invade surrounding tissues, results from mutations in critical genes involved in key cellular events. These genetic alterations can affect cell-surface-associated receptors, elements of signaling pathways, or components of the cell cycle clock, conferring a gain or a loss of relevant metabolic functions of the cells. The understanding of such phenomena may allow the development of more efficacious forms of cancer treatment. Examples are therapies specifically directed against overexpressed epidermal growth factor receptor, hyperactive Ras, excessively stimulated Raf-1, overproduced ornithine decarboxylase, or aberrantly activated cyclin-dependent kinases. The applicability of some of these approaches is now being assessed in patients suffering from primary malignant central nervous system tumors that are not amenable to current therapeutic modalities. Another potentially useful therapeutic strategy against such tumors involves the inhibition of hyperactive or overexpressed protein kinase C (PKC). This strategy is justified by the decrease in cell proliferation and invasion following inhibition of the activity of this enzyme observed in preclinical glioma models. Thus, interference with PKC activity may represent a novel form of experimental cancer treatment that may simultaneously restrain the hyperproliferative state and the invasive capacity of high-grade malignant gliomas without inducing the expected toxicity of classical cytotoxic agents. Of note, the experimental use of PKC-inhibiting agents in patients with refractory high-grade malignant gliomas has indeed led to some clinical responses. The present paper reviews the current status of the biochemistry and molecular biology of PKC, as well as the possibilities for developing novel anti-PKC-based therapies for central nervous system malignancies.
da Rocha
A B
AB
South-American Office for Anticancer Drug Development (SOAD), Comprehensive Cancer Center, Lutheran University of Brazil, Canoas, RS, Brazil. brondani@terra.com.br
Mans
D R A
DR
Regner
A
A
Schwartsmann
G
G
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D054713:Bryostatins; D002455:Cell Division; D002648:Child; D002675:Child, Preschool; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007783:Lactones / Q000627:therapeutic use; D018942:Macrolides; D009154:Mutation; D009281:Naphthalenes / Q000627:therapeutic use; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D010641:Phenotype; D011493:Protein Kinase C / Q000037:antagonists & inhibitors* / Q000502:physiology; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019311:Staurosporine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D054713:Bryostatins; D004791:Enzyme Inhibitors; D007783:Lactones; D018942:Macrolides; D009281:Naphthalenes; D009363:Neoplasm Proteins; C046785:bryostatin 1; D011493:Protein Kinase C; D019311:Staurosporine; C058819:calphostin C; D013110:Sphingosine; C005682:safingol